No Detail Found!

Managing Hepatic Encephalopathy - Combination of Lactulose and Rifaximin Versus Lactulose Monotherapy: A Systematic Review and Meta-analysis

Author(s)
Saad Khalid Dow Medical College, Dow University of Health Sciences, Karachi, Pakistan
Uzair Aslam Dow Medical College, Dow University of Health Sciences, Karachi, Pakistan
Iftikhar Haider Naqvi Department of Medicine, Dow University of Health Sciences, Karachi, Pakistan
Mahima Khatri Dow Medical College, Dow University of Health Sciences, Karachi, Pakistan
Mishal Shan Siddiqui Dow Medical College, Dow University of Health Sciences, Karachi, Pakistan.
Zoha Allahuddin Dow Medical College, Dow University of Health Sciences, Karachi, Pakistan
Abstract
Hepatic Encephalopathy (HE), a neuropsychiatric complication of hepatic failure, is currently managed with lactulose as first-line treatment followed by other adjuncts if needed. In this meta-analysis, we determined the efect of lactulose and rifaximin combination in terms of eficacy and mortality reduction compared to lactulose alone. Materials and Methods: We searched databases (PubMed, BioMed Central, and Cochrane-Central) until July, 2022 for original studies inspecting the efects of Rifaximin and Lactulose (combination therapy) vs. lactulose as a monotherapy in the treatment of HE on outcomes of clinical eficacy, hospital stay length, HE recurrence, drugs' side efects and mortality. Data was analyzed via Review Manager (version5.4.1) and OpenMetaAnalyst. Relative risks (RR) and weighted mean diferences (WMD) with 95% confidence intervals were calculated. Results: Fifteen studies with 4327 patients were included. Pooled analysis showed combination therapy to be associated with a significantly lower mortality rate in patients having HE when compared to lactulose alone (RR 0.71 95% CI 0.58-0.88, P=0.002, I2= 68%), and clinical eficacy was also improved in the combination group (RR 1.33, 95%CI 1.19-1.48, P <0.00001, I2= 52%). HE recurrence rate, adverse events, and length of hospital stay did not significantly difer among the two groups (RR= 0.61, 95 % CI= 0.35 to 1.05, P= 0.08, I2= 84%), (RR= 0.92, 95% CI= 0.51 to 1.69, P= 0.80, I2 = 0) and (WMD -1.52, 95% CI -3.22 to 0.18, P=0.08, I2 = 83%) respectively. Conclusion: Combination therapy shows survival benefit and superior clinical eficacy over lactulose monotherapy in managing hepatic encephalopathy.
Publication Details
Page(s) 74-84
Published Journal: Liaquat National Journal of Primary Care, Volume: 6, Issue: 1, Year: 2024

Request the full text from PASTIC

Keywords
Hepatic Encephalopathy, Systematic review, Meta-analysis, Rifaximin, Lactulose
References
Vilstrup H,Amodio P,Bajaj J,Cordoba J,Ferenci P,Mullen KD .2014 .Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the study of liver diseases and the European Association for the study of the liver. Hepatology, 60(2) : 715-35.
Lunia MK,Sharma BC,Sachdeva S. .2013 .Small intestinal bacterial overgrowth and delayed orocecal transit time in patients with cirrhosis and low-grade hepatic encephalopathy. Hepatol Int, 7(1) : 268-73.
Prakash R,Mullen KD .2010 .Mechanisms, diagnosis and management of hepatic encephalopathy. Nat Rev Gastroenterol Hepatol, 7(9) : 515-25.
Montagnese S,De Pittà C,De Rui M,Corrias M,Turco M,Merkel C .2014 .Sleep-wake abnormalities in patients with cirrhosis. Hepatology, 59(2) : 705-12.
Bajaj JS,Wade JB,Gibson DP,Heuman DM,Thacker LR,Sterling RK .2011 .The multi- dimensional burden of cirrhosis and hepatic encephalopathy on patients and caregivers. Am J Gastroenterol, 106(9) : 1646-53.
Ferenci P .2017 .Hepatic encephalopathy. Gastroenterol Rep (Oxf), 5(2) : 138-47.
Bleibel W,Al-Osaimi AM .2012 .Hepatic encephalopathy. Saudi J Gastroenterol, 18(5) : 101123-3767.
Hasan S,Datta S,Bhattacherjee S,Banik S,Saha S,Bandyopadhyay D. .2018 .A randomized controlled trial comparing the eficacy of a combination of rifaximin and lactulose with lactulose only in the treatment of overt hepatic encephalopathy. J Assoc Physicians India, 66(1) : 32-36.
Ahire K,Sonawale A .2017 .Comparison of rifaximin plus lactulose with the lactulose alone for the treatment of hepatic encephalopathy. J Assoc Physicians India, 65(8) : 42-6.
Butt NI,Butt UI,Kakar AATK,Malik T,Siddiqui AM .2018 .Is lactulose plus rifaximin better than lactulose alone in the management of hepatic encephalopathy. J Coll Physicians Surg Pak, 02(2) : 115-7.
Wang Z,Chu P,Wang W. .2019 .Combination of rifaximin and lactulose improves clinical eficacy and mortality in patients with hepatic encephalopathy. Drug Des Devel Ther, 13 : 1-11.
Hutton B,Salanti G,Caldwell DM,Chaimani A,Schmid CH,Cameron C .2015 .The PRISMA extension statement for reporting of systematic reviews incorporating network meta- analyses of health care interventions: checklist and explanations. Ann Intern Med, 162(11) : 777-84.
Higgins JP,Altman DG,Gøtzsche PC,Jüni P,Moher D,Oxman AD .2011 .The cochrane collaboration's tool for assessing risk of bias in randomised trials. BMJ, 343 : .
Wells GA,Shea B,O'Connell DA,Peterson J,Welch V,Losos M .2021 .The Newcastle- Ottawa Scale (NOS) for assessing the quality of non-randomised studies in meta-analyses. [accessed 24 October, : .
Higgins JPT,Thompson SG,Deeks JJ,Altman DG .2003 .Measuring inconsistency in meta- analyses. BMJ, 327 : 557-60.
Kang SH,Lee YB,Lee JH,Nam JY,Chang Y,Cho H .2017 .Rifaximin treatment is associated with reduced risk of cirrhotic complications and prolonged overall survival in patients experiencing hepatic encephalopathy. Aliment Pharmacol Ther, 46(9) : 845-55.
Sharma BC,Sharma P,Lunia MK,Srivastava S,Goyal R,Sarin SK .2013 .A randomized, double- blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy. Am J Gastroenterol, 108(9) : 1458-63.
Gill ML,Niaz T,Aziz H,Khan S. .2014 .1): S215. J Hepatol, 8278(14) : 60602-4.
Haq MIU,Salim A,Afzal MS,Malik K,Amin J,Butt AK .2014 .Comparison of rifaximin and lactulose with lactulose alone in the treatment of acute hepatic encephalopathy in patients with liver cirrhosis. Proceeding SZPGMI, 28(2) : 115-9.
Poudyal NS,Chaudhary S,Kc S,Paudel BN,Basnet BK,Mandal A .2019 .4): e4363. Cureus, 11 : .
Bajaj JS,O'Leary JG,Tandon P,Wong F,Kamath PS,Biggins SW .2019 .Targets to improve quality of care for patients with hepatic encephalopathy: data from a multi-centre cohort. Aliment Pharmacol Ther, 49(12) : 1518-27.
Courson A,Jones GM,Twilla JD .2016 .Treatment of acute hepatic encephalopathy: comparing the efects of adding rifaximin to lactulose on patient outcomes. J Pharm Pract, 29(3) : 212-17.
Hussain T,Sattar M,Mustafa S,Batool U,Iqbal S,Hassan B .2020 .Comparing eficacy of rifaximin plus lactulose vs. lactulose alone in treating hepatic encephalopathy. J Rawalpindi Med Coll, 24(4) : 1418-43.
Ahmed S,Ahmad S,Khan SU .2018 .Lactulose alone versus lactulose + rifaximin for the management of hepatic encephalopathy. Pak J Med Health Sci, 12(3) : 1269-71.
Gao ZM. .2012 .Clinical observation of rifaximin combined with lactulose for the treatment of hepatic encephalopathy. J China Tradit Chinese Med Inform, 4(2) : 381.
Chang C,Huang CH,Tseng HJ,Yang FC,Chien RN .2021 .Real-world experience of the one- year eficacy of rifaximin add-on to lactulose is superior to lactulose alone in patients with cirrhosis complicated with recurrent hepatic encephalopathy in Taiwan. J Pers Med, 11(6) : 478.
Ahmed RS,Adnan M,Jabeen H M .2018 .Eficacy of lactulose vs. lactulose with rifaxamin in patients with hepatic encephalopathy: a randomized control trial. J Muhammad Med Coll, 9(1) : 39-41.
Weissenborn K. .2019 .Hepatic encephalopathy: definition, clinical grading and diagnostic principles. Drugs, 79(Suppl 1) : 5-9.
Kornerup LS,Gluud LL,Vilstrup H,Dam G. .2018 .Update on the therapeutic management of hepatic encephalopathy. Curr Gastroenterol Rep, 20(5) : 21.
Gluud LL,Vilstrup H .2016 .Nonabsorbable disaccharides for hepatic encephalopathy: A systematic review and meta-analysis. Hepatology, 64(3) : 908-22.
Lawrence KR .2008 .Rifaximin for the treatment of hepatic encephalopathy. Pharmacotherapy, 28(8) : 1019-32.
Zhu GQ,Shi KQ,Huang S,Wang LR,Lin YQ,Huang GQ .2015 .Systematic review with network meta-analysis: the comparative efectiveness and safety of interventions in patients with overt hepatic encephalopathy. Aliment Pharmacol Ther, 41(7) : 624-35.
Nef GW,Flamm SL,Mullen KD,Barrett AC,Bortey E,Paterson C .2013 .5): S-451. Gastroenterology, 5085(13) : 61665-0.
Bass NM,Mullen KD,Sanyal A,Poordad F,Nef G,Leevy CB .2010 .Rifaximin treatment in hepatic encephalopathy. N Eng J Med, 362(12) : 1071-81.
Said VJ,Garcia-Trujillo E .2019 .Beyond lactulose: treatment options for hepatic encephalopathy. Gastroenterol Nurs, 42(3) : 277-85.
Montagnese S,Russo FP,Amodio P,Burra P,Gasbarrini A,Loguercio C .2018 .A clinical practice guideline by the Italian Association for the study of the liver (AISF). Dig Liver Dis, 11(2) : 190-205.
Butt Z,Jadoon NA,Salaria ON,Mushtaq K,Riaz IB,Shahzad A .2013 .Diabetes mellitus and decompensated cirrhosis: Risk of hepatic encephalopathy in diferent age groups. J Diab, 5(4) : 12067-0407.
Chirapongsathorn S,Krittanawong C,Enders FT,Pendegraft R,Mara KC,Borah BJ .2018 .Incidence and cost analysis of hospital admission and 30-day readmission among patients with cirrhosis. Hepatol Commun, 2(2) : 188-98.
Tapper EB,Halbert B,Mellinger J .2016 .Rates of and reasons for hospital readmissions in patients with cirrhosis: a multistate populationbased cohort study. Clin Gastroenterol Hepatol, 04(8) : 1181-8.
0

Citations

0

Downloads

53

Views